All In Biotech

Drug Trial Radar · NCT06712355

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

A Phase III, Multisite, Double-blinded Randomized Trial of BNT327 in Combination With Chemotherapy (Etoposide/Carboplatin) Compared to Atezolizumab in Combination With Chemotherapy (Etoposide/Carboplatin) in Participants With First-line Extensive-stage Small-cell Lung Cancer

Last checked: Nov 20, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 621 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

621

Planned (sponsor's estimate)

Start

Feb 3, 2025

Primary completion

Apr 2029

Study completion Jul 2029

Sponsor

Lead sponsor
BioNTech SEIndustry
Sponsor type
Industry
Collaborators
Bristol-Myers Squibb
First posted
Dec 2, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase III, multisite, randomized, double-blinded study to investigate pumitamig (BNT327) combined with chemotherapy (etoposide/carboplatin) compared to atezolizumab combined with chemotherapy (etoposide/carboplatin) for the treatment of participants with previously untreated extensive-stage small-cell lung cancer (ES-SCLC).

Conditions

  • Extensive-stage Small-cell Lung Cancer

Interventions

  • PumitamigDrug

    Intravenous infusion

  • AtezolizumabDrug

    Intravenous infusion

  • EtoposideDrug

    Intravenous infusion and capsules

  • Carboplatin (or cisplatin if carboplatin is not tolerated)Drug

    Intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survival (OS)Time frame: Up to approximately 46 months

Locations

225 sites in 14 countries. Site status is shown where the registry gives one.

  • ACRC Arizona Clinical Research Center

    Tucson, Arizona · Recruiting

  • Clermont Oncology Center

    Clermont, Florida · Terminated

  • Cancer Care Centers of Brevard, Inc

    Palm Bay, Florida · Recruiting

  • Northside Hospital Atlanta

    Atlanta, Georgia · Recruiting

  • Illinois Cancer Specialists

    Niles, Illinois · Recruiting

  • Fort Wayne Medical Oncology and Hematology, Inc

    Fort Wayne, Indiana · Recruiting

  • McFarland Clinic

    Ames, Iowa · Recruiting

  • Helen G. Nassif Community Cancer Center

    Cedar Rapids, Iowa · Recruiting

  • Baptist Health Hardin Cancer Center

    Elizabethtown, Kentucky · Recruiting

  • LSU Health Baton Rouge - North Clinic

    Baton Rouge, Louisiana · Recruiting

  • Our Lady of the Lake Hospital, Inc.

    Baton Rouge, Louisiana · Recruiting

  • Frederick Health Hospital- James M Stockman Cancer Institute

    Frederick, Maryland · Recruiting

  • Beth Israel Lahey Health - Lahey Hospital & Medical Center (LHMC), Lahey Clinic Medical Center

    Burlington, Massachusetts · Recruiting

  • Baptist Cancer Center

    Southaven, Mississippi · Recruiting

  • Washington University School of Medicine

    St Louis, Missouri · Recruiting

  • Nebraska Hematology-Oncology (NHO)

    Lincoln, Nebraska · Recruiting

  • Cornell University - NewYork-Presbyterian/Weill Cornell Medical Center

    New York, New York · Recruiting

  • White Plains Hospital

    White Plains, New York · Recruiting

  • Cleveland Clinic - Akron General Hematology & Oncology

    Akron, Ohio · Recruiting

  • Cleveland Clinic Mercy Hospital Cancer Center

    Canton, Ohio · Recruiting

  • The Christ Hospital Cancer Center

    Cincinnati, Ohio · Recruiting

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio · Recruiting

  • The Cleveland Clinic Cancer Center at Fairview Hospital, Moll Pavilion

    Cleveland, Ohio · Recruiting

  • Cleveland Clinic Foundation

    Cleveland, Ohio · Recruiting

  • Kettering Medical Center

    Kettering, Ohio · Recruiting

  • Cleveland Clinic - Hillcrest Hospital

    Mayfield Heights, Ohio · Recruiting

  • St. Luke's Physician Group - St. Luke's Cancer Care Associates

    Fountain Hill, Pennsylvania · Recruiting

  • West Cancer Center & Research Institute

    Germantown, Tennessee · Recruiting

  • University of Tennessee Medical Center

    Knoxville, Tennessee · Recruiting

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Millennium Research and Clinical Development, LLC

    Houston, Texas · Terminated

  • Texas Oncology Cancer Center

    Sugar Land, Texas · Recruiting

  • Virginia Cancer Specialists

    Fairfax, Virginia · Recruiting

  • Hematology Oncology Associates of Fredericksburg, Inc.

    Fredericksburg, Virginia · Recruiting

  • Virginia Commonwealth University School of Medicine

    Richmond, Virginia · Recruiting

  • Shenandoah Oncology

    Winchester, Virginia · Recruiting

  • Cairns Hospital

    Cairns, Australia · Recruiting

  • Sir Charles Gairdner Hospital (SCGH)

    Nedlands, Australia · Recruiting

  • Royal North Shore Hospital

    Saint Leonards, Australia · Recruiting

  • Liverpool Hospital

    Sydney, Australia · Recruiting

Showing 40 of 225 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.